|
Jul 20, 2017 |
REDWOOD CITY, Calif., July 20, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2017 financial results. The call and webcast will follow the release of the second quarter financial results aft...
|
|
|
Jul 12, 2017 |
REDWOOD CITY, Calif., July 12, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the 15th St. Gallen International Breast Cancer Conference Expert Panel endorsed the use of genomic tests in early-stage breast cancer and recognized the Oncotype DX Breast Recurrence Score® test for its prognostic ability as well as it...
|
|
|
Jun 2, 2017 |
REDWOOD CITY, Calif., June 2, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of eight studies that provide additional evidence of the value of Oncotype DX® tests in predicting clinically meaningful endpoints and outcomes across multiple cancer types. The data from patients with invasive breast, ductal...
|
|
|
May 30, 2017 |
REDWOOD CITY, Calif., May 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from eight Oncotype DX® studies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 2-6 at McCormick Place in Chicago. These presentations represent data ac...
|
|
|
May 25, 2017 |
REDWOOD CITY, Calif., May 25, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 4:30 p.m. Eastern Time.
To access the live and subsequently archived webcast of the presentation, go to the Investor Relations sec...
|
|
|
May 13, 2017 |
REDWOOD CITY, Calif., May 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two Oncotype DX® Genomic Prostate Score™ (GPS) test analyses based on a prospective, multi-center, 1,200-patient study. Results of one analysis, presented at the American Urological Association (AUA) 2017 Annual Meeting, pr...
|
|
|
May 12, 2017 |
REDWOOD CITY, Calif., May 12, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large, community-based, multi-center clinical validation study conducted at Kaiser Permanente, confirming that the Oncotype DX® Genomic Prostate Score™ (GPS) test is a strong independent predictor ...
|
|
|
May 10, 2017 |
REDWOOD CITY, Calif., May 10, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Wednesday, May 17, 2017 at 11:20 a.m. Pacific Time.
To access the live and subsequently archived webcast of the presentation, go to the In...
|
|
|
May 9, 2017 |
REDWOOD CITY, Calif., May 9, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2017.
Total revenue was $84.0 million in the first quarter of 2017, compared with $80.9 million in the first quarter of 2016, an increase of 4 percent.
U.S. produ...
|
|
|
May 4, 2017 |
REDWOOD CITY, Calif., May 4, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX® Genomic Prostate Score™ (GPS). The draft LCD recomm...
|
|